JP Morgan Healthcare Conference | GenomeWeb

JP Morgan Healthcare Conference

Developers said Illumina's decision to tap into the cancer screening market is not surprising because of its potentially huge size.

Westin St. Francis Hotel, San Francisco, site of the JP Morgan Healthcare Conference

Executives from Luminex, Exact Sciences, T2 Biosystems, and Singulex provided updates on their companies' businesses on the final day of the conference.

Executives from several life science research tool and diagnostic firms provided conference attendees with updates on their businesses.

The chemistry will be single-molecule, based on hybridization, and will not require amplification, enzymes, or library prep, the firm said.

Quiet Down

MedCity News says the real highlight of the JP Morgan Healthcare conference was when 23andMe CEO Anne Wojcicki was shushed for talking during her own company's presentation.

Executives from Thermo Fisher Scientific, Qiagen, Danaher, Counsyl, Human Longevity, and Adaptive Biotechnologies provided business updates to conference goers.

Executives from the sequencing tech firms provided attendees with an update on recently launched products and platforms, and future technology developments.

Executives from 23andMe, Myriad Genetics, Genomic Health, and Alere provided updates on their companies at the JP Morgan Healthcare Conference in San Francisco.

The company also announced the Infinium XT genotyping array for analyzing large sample numbers, and provided preliminary earnings for Q4 and full-year 2015.

San Francisco

Officials from Luminex and BioNano Genomics provided strategic updates at the conference.


In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.